( MINNEAPOLIS--(BUSINESS WIRE)--Mar 26 2...)Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile,Health

MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results from the Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positive clinical profile of the Endeavor(R) drug-eluting coronary stent and bring to nearly 1,300 the number of Endeavor patients who have at least two years of follow-up. Significantly, among those 1,300 Endeavor patients, there have been no reported cases of late stent thrombosis using the independent, pre-specified clinical trial protocol definitions for thrombosis. The results were presented today during the 56th Annual Scientific Session of the American College of Cardiology (ACC) conference in New Orleans.

Those in the 436-patient ENDEAVOR III trial are being followed out to five years. The clinical data reported at ACC as part of the study design indicate that the Endeavor stent continues to exhibit an excellent safety profile while delivering sustained efficacy and a low need for repeat procedures that is consistent with the overall Endeavor clinical program. At two years, the rate of Major Adverse Cardiac Events - a composite safety measure of death, repeat procedures and myocardial infarction (MI) - was reported to be 9.3% for Endeavor and 11.6% for the Cypher stent also studied in the ENDEAVOR III trial (p = 0.47). There was no statistically significant difference in the need for repeat procedures, or Target Lesion Revascularization (7.0% and 4.5% for Endeavor and Cypher, respectively, p = 0.50), or all-cause mortality (1.6% for Endeavor and 4.5% for Cypher, p = 0.14). However, fewer patients experienced heart attacks (MI) when treated with the Endeavor stent (0.6% vs. 3.6% for Cypher, p = 0.04) and the combined rate of heart attack and death also was statistically significantly lower among patients randomized to the Endeavor stent (2.2% vs. 7.1% for Cypher, p = 0.013).

Confidence in Endeavor safety

Worldwide, Medtronic has approximately 2,100 Endeavor patients enr
'"/>

Page: 1 2 3
Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis